




Conférence

Centre de recherche du CHU de Québec-Université Laval



Dr John Stagg

Professeur adjoint, Faculté de pharmacie,
Université de Montréal

Invité par Dr Yves Fradet

Date : 7 décembre 2017

Heure : 10 h

Lieu : Amphithéâtre du CRCEO/L'Hôtel-Dieu de Québec
6, rue McMahon, Québec (QC)



AXE ØNCOLOGIE



« The adenosine pathway in immuno-oncology »

John Stagg's laboratory identified CD73 as a new target in immuno-oncology. Since 2010, John participated in the development of several adenosine-targeting therapies now entering clinical trials. Extracellular adenosine, generated by the ectonucleotidases CD39 and CD73, is a newly recognized "immune checkpoint" that interferes with anti-tumor immune responses. In the past recent years, adenosine-targeting agents have been developed and are currently being evaluated in phase I clinical trials. I will summarize the role of the CD73-adenosine axis in tumor immunity and the recent developments in adenosine-targeting drugs and potential toxicities associated with adenosine inhibitors.

Note :

Prière d'aviser vos étudiants gradués et stagiaires postdoctoraux afin d'avoir la participation de tous.

Visioconférence

CHUL (E00320) HSS (Salle 4)